<DOC>
	<DOCNO>NCT02556203</DOCNO>
	<brief_summary>To assess whether rivaroxaban-based anticoagulation strategy , follow successful TAVR , compare antiplatelet-based strategy , superior reduce death first thromboembolic event ( DTE ) . To assess primary bleed event ( PBE ) rivaroxaban-based strategy compare antiplateletbased strategy , follow TAVR .</brief_summary>
	<brief_title>Global Study Comparing rivAroxaban-based Antithrombotic Strategy antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement Optimize Clinical Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Successful TAVR ( Transcatheter Aortic Valve Replacement ) aortic valve stenosis ( either native valveinvalve ) By iliofemoral subclavian access With approved/marketed device Atrial fibrillation ( AF ) , current previous , ongoing indication oral anticoagulant treatment Any indication continue treatment oral anticoagulant ( OAC ) Known bleed diathesis ( limited active internal bleeding , clinically significant bleeding , platelet count â‰¤ 50,000/mm3 screening , hemoglobin level &lt; 8.5 g/dL , active peptic ulcer know gastrointestinal ( GI ) bleeding , history intracranial hemorrhage subdural hematoma ) Any ongoing absolute indication dual antiplatelet therapy ( DAPT ) time screen unrelated TAVR procedure Clinically overt stroke within last 3 month Planned coronary vascular intervention major surgery Severe renal impairment ( eGFR &lt; 30 mL/min/1.73 m2 ) dialysis , postTAVR unresolved acute kidney injury renal dysfunction stage 2 high Moderate severe hepatic impairment ( ChildPugh Class B C ) hepatic disease associate coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TAVR</keyword>
	<keyword>TAVI</keyword>
	<keyword>Transfemoral aortic valve implantation</keyword>
</DOC>